A Study of TORL-5-700 in Relapsed/Refractory Non Hodgkin's Lymphoma
A Phase 1/2, First-in-Human, Open-Label, Multicenter Study of TORL-5-700 as a Monotherapy and in Combination for Participants With Relapsed or Refractory Non-Hodgkin Lymphoma
TORL Biotherapeutics, LLC
155 participants
Mar 31, 2026
INTERVENTIONAL
Conditions
Summary
A Phase 1/2 study to evaluate safety, tolerability, and anticancer activity of TORL-5-700 as a monotherapy and in combination in R/R NHL
Eligibility
Inclusion Criteria5
- Confirmed B-NHL, including but not limited to de novo DLBCL; FL, Grades 1 to 3A; MCL; transformed lymphoma (tFL, RT) and FL Grade 3B; MZL and MALT.
- Eastern Cooperative Oncology Group (ECOG) performance status less than or equal to 2.
- At least 1 measurable lesion per Lugano criteria.
- Tumor tissue is available.
- Adequate organ function
Exclusion Criteria7
- T-cell lymphoma
- CLL or SL
- Burkitt lymphoma and high-grade B-cell lymphoma
- CNS involvement
- Peripheral neuropathy > Grade 2
- Uncontrolled medical conditions
- Viral infections
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Part 1: Monotherapy Dose Escalation - TORL-5-700 Administered once every three weeks
Part 2: Monotherapy Expansion - TORL-5-700 at Maximum tolerated Dose (MTD)/Recommended Phase 2 Dose (RP2D) Administered once every three weeks
Part 3: Combination Evaluation - TORL-5-700 at MTD/RP2D administered every three weeks in combination with another agent
Locations(3)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07439653